Sanofi has had a “positive and constructive” meeting with the US Food and Drug Administration to get its switch of erection dysfunction drug Cialis back on track.
Speaking as the Paris, France-based firm reported its Q2 results, Consumer Healthcare head Julie Van Ongevalle said Sanofi
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?